trial · primary record
Nerandomilast
Interstitial Lung Diseases
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 466 |
| Primary completion | 2028-12-12 |
| Primary endpoint | Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 52 |
| Registry ID | NCT07540988 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:32.762Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07540988
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- NERANDOMILAST · approval
- NERANDOMILAST · approval
- Nerandomilast · compound